New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures
Abstract
Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2020
- Source ID
- 10.1016/j.jalz.2019.06.4956
Entities
People
- Adam L. Boxer
- Ajay Verma
- Bradford C. Dickerson
- Bradley F. Boeve
- Brian M. Alexander
- Carole Ho
- Chiadi U. Onyike
- Debra Niehoff
- Earl Ray Dorsey
- Edward D. Huey
- Frances Mcfarland
- Holly D. Soares
- Howard Feldman
- Howard Fillit
- Howard Rosen
- Jonathan D. Rohrer
- Kenneth Rockwood
- M. Gold
- Margaret Sutherland
- Mario Masellis
- Michael A. Panzara
- Michael C. Irizarry
- Murray Grossman
- Nadine Tatton
- Robert N. Schuck
- Robert Paul
- Rodney Pearlman
- Sabrina Paganoni
- Stephen P. Arneric
- Susan L.-j. Dickinson
- William J. Marks
Organizations
- Association for Frontotemporal Degeneration
- National Institutes of Health